pembrolizumab + MK-0482 + carboplatin + pemetrexed

This is an investigational combination regimen comprising **pembrolizumab**, **MK-0482**, **carboplatin**, and **pemetrexed** used primarily in early-phase clinical trials for advanced solid tumors. - **Pembrolizumab** is a humanized IgG4 monoclonal antibody that inhibits PD-1 (programmed cell death protein 1), thereby blocking the interaction with its ligands PD-L1 and PD-L2 and enhancing T-cell mediated antitumor immunity. - **MK-0482** is a novel humanized IgG4 monoclonal antibody targeting the inhibitory receptor ILT3 (immunoglobulin-like transcript 3) present on myeloid-derived suppressor cells in the tumor microenvironment; blocking ILT3 potentially relieves myeloid-driven immunosuppression and synergizes with immune checkpoint blockade[2][3]. - **Carboplatin** and **pemetrexed** are established chemotherapy agents: carboplatin is a platinum-based DNA crosslinker, and pemetrexed is a multitargeted antifolate that disrupts folate-dependent metabolic processes critical for cellular replication. - The combination is under investigation for advanced/metastatic cancers (notably non-small cell lung cancer and pancreatic cancer) as part of a broader effort to enhance antitumor immune response and improve clinical efficacy relative to chemotherapy or immunotherapy alone[1][2].

Brand names

Keytruda (for pembrolizumab)Alimta (for pemetrexed)

Other names

pembrolizumabMK-0482MK0482MK 0482